13. Percutaneous intervention for structural heart disease

Cerebral embolic protection during TAVR

Protected TAVR
Objective
does cerebral embolic protection (CEP) during TAVR reduce the risk of stroke / using the Sentinal CEP device
Study
prospective, multicentre, randomised trial
Population
patients eligible to undergo TAVR for treatment of aortic stenosis
Endpoints
clinical stroke within 72 hours after TAVR or before discharge
Conclusion
the use of CEP during TAVR for aortic stenosis does not have a significant effect on the incidence of periprocedural stroke
Kapadia et al. N.Engl.J. Med 2022; 387:1253-63
Receive our newsletter


The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved